Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
Novo Nordisk has just added a new target to Eli Lilly's advertising campaign: a federal judge in New Jersey. The Danish group, maker of Wegovy and Ozempic, is suing its competitor for false advertising and unfair competition. On Friday, July 24, it filed for a temporary injunction to have the ads targeting Eli Lilly removed immediately.